



**Department of Vermont Health Access  
Pharmacy Benefits Management Program  
*DUR Board Meeting Agenda***

---

February 18, 2020: 6:30 – 8:30 p.m.

- **Executive Session** **6:00 - 6:30**
  
- **Introductions and Approval of DUR Board Minutes** **6:30 - 6:35**  
(Public Comment Prior to Board Action)
  
- **DVHA Pharmacy Administration Updates** **6:35 - 6:40**
  
- **Medical Director Update** **6:40 - 6:45**
  
- **Follow-up Items from Previous Meetings** **6:45 - 6:50**
  - None at this time
  
- **RetroDUR/ProDUR** **6:50- 7:15**
  - Introduce: BP Medication Adherence and Use of NSAIDs in Chronic Kidney Disease
  - Data Presentation: Inappropriate Use of Antibiotics
  
- **Clinical Update: Drug Reviews** **7:15-7:45**  
(Public comment prior to Board action)

**Biosimilar Drug Reviews**

- None at this time

**Full New Drug Reviews**

(Any new drug reviews that also fall within the Therapeutic Class review will be discussed during the Therapeutic Class Review)

- Adhansia XR® (methylphenidate hydrochloride ER)
  - Baqsimi® (glucagon nasal powder)
  - Ezallor® (rosuvastatin)
  - Gvoke® (glucagon injection)
  - Katerzia® (amlodipine oral sus)
  - Minolira® (minocycline hydrochloride ER)
  - Rinvoq® (upadacitinib)
  - Sunosi® (solriamfetol)
  - Zelnorm® (tegaserod maleate)
  - Zolgensma® (onasemnogene abeparvovec- xioi)
  - Zulresso® (brezamlolne)
- 
- **New Managed Therapeutic Drug Classes** **7:45 -7:45**  
(Public comment prior to Board action)

- None at this time
  
- **Therapeutic Drug Classes – Periodic Review** **7:45 - 8:25**  
(Public comment prior to Board action)
    - Acne Agents
    - Antibiotics, Miscellaneous (this includes the macrolides)
    - Antivirals- Influenza, HSV, and CMV Agents
    - Antivirals, Topical
    - Cephalosporins and Related Antibiotics
    - Fluoroquinolones
    - Skeletal Muscle Relaxants
    - Tetracyclines
  
- **Review of Newly-Developed/Revised Criteria** **8:25 –8: 25**
    - None at this time
  
- **General Announcements** **8:25 – 8:30**
    - **Selected FDA Safety Alerts**
    - **FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR)**
    - [https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin?utm\\_campaign=FDA%20MedWatch%20-%20gabapentin%20and%20pregabalin%29%3A%20Drug%20Safety%20Communication&utm\\_medium=email&utm\\_source=Eloqua](https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin?utm_campaign=FDA%20MedWatch%20-%20gabapentin%20and%20pregabalin%29%3A%20Drug%20Safety%20Communication&utm_medium=email&utm_source=Eloqua)
  
- **Adjourn** **8:30**